Aspira Women’s Health GAAP EPS of -$0.07, revenue of $2.4M

* Aspira Women’s Health press release [https://seekingalpha.com/pr/20199009-aspira-announces-second-quarter-2025-financial-results-and-provides-business-update] (OTC:AWHL [https://seekingalpha.com/symbol/AWHL]): Q2 GAAP EPS of -$0.07.
* Revenue of $2.4M (-0.8% Y/Y).
* Reported average unit prices ("AUP") grew 12% year over year for the commercial product portfolio, which is comprised of non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus® and OvaWatch®.
* The AUP for Ova1Plus increased 11% year over year, while OvaWatch, still in the earlier stages of market adoption, increased AUPs by 16% year over year.
* Cash used in operations was $4.8 million for the six months ended June 30, 2025, as compared to $8.2 million in the six months ended June 30, 2024.

MORE ON ASPIRA WOMEN’S HEALTH

* Financial information for Aspira Women’s Health [https://seekingalpha.com/symbol/AWHL/income-statement]